3-chloro-N-(6-chloropyridin-2-yl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-chloro-N-(6-chloropyridin-2-yl)benzamide
• 化学式: C₁₂H₈Cl₂N₂O
• 分子量: 267.114
• InChiKey: FCJWDXAXERKUEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-chloro-N-(6-chloropyridin-2-yl)benzamide 、 3-羟基吡啶 在 copper(l) iodide 、 N,N-二甲基甘氨酸盐酸盐 、 caesium carbonate 作用下， 生成 3-chloro-N-(6-pyridin-3-yloxypyridin-2-yl)benzamide
  参考文献：
  名称：

  Discovery of VU0431316: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety

  摘要：

  Development of SAR in an aryl ether series of mGlu(5) NAMs leading to the identification of pyrazine analog VU0431316 is described in this Letter. VU0431316 is a potent and selective non-competitive antagonist of mGlu(5) that binds at a known allosteric binding site. VU0431316 demonstrates an attractive DMPK profile, including moderate clearance and good bioavailability in rats. Intraperitoneal (IP) dosing of V1J0431316 in a mouse marble burying model of anxiety, an assay known to be sensitive to mGlu(5) antagonists and other anxiolytics, produced dose proportional effects. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.06.003
• 作为产物：
  描述：

  2-氨基-6-氯吡啶 、 3-氯苯甲酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以40%的产率得到3-chloro-N-(6-chloropyridin-2-yl)benzamide
  参考文献：
  名称：

  N-吡啶基苯甲酰胺：一种新的抗分枝杆菌化合物的等排方法

  摘要：

  设计并制备了一系列N-吡啶基苯甲酰胺，以研究等排和位置异构对抗分枝杆菌活性的影响。与先前发表的等排N-吡嗪基苯甲酰胺进行比较，试图绘制此类化合物的结构-活性关系。我们总共制备了 44 种不同的化合物，其中 14 种对结核分枝杆菌H37Ra 的最低抑菌浓度 (MIC) 值低于 31.25 µg/ml，最有希望的是N- (5-氯吡啶-2-基)-3-(三氟甲基)苯甲酰胺 ( 23 ) 和N- (6-氯吡啶-2-基)-3-(三氟甲基)苯甲酰胺 ( 24 )，MIC = 7.81 µg/ml (26 µg)米）。五种化合物对结核分枝杆菌H37Ra、耻垢分枝杆菌和金黄色分枝杆菌具有广谱抗分枝杆菌活性。N- (吡啶-2-基)苯甲酰胺通常比N- (吡啶-3-基)苯甲酰胺更具活性，表明N-吡嗪基苯甲酰胺亲本结构中的N -1可能比N-4对抗分枝杆菌活性更重要. 观察到标题化合物的边际抗菌和抗真菌活性。标题化合

  DOI：

  10.1111/cbdd.13804

文献信息

• Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists
  作者：Santosh S. Kulkarni、Barbara Nightingale、Christina M. Dersch、Richard B. Rothman、Amy Hauck Newman

  DOI：10.1016/j.bmcl.2006.04.032

  日期：2006.7

  A series of diaryl amides was designed and synthesized as novel nonethynyl mGluR5 antagonists. The systematic variation of the pharmacophoric groups led to the identification of a lead compound that demonstrated micromolar affinity for the mGluR5. Further optimization resulted in compounds with improved binding affinities and antagonist profiles, in vitro. (c) 2006 Elsevier Ltd. All rights reserved.
• <i>N</i> ‐pyridinylbenzamides: an isosteric approach towards new antimycobacterial compounds
  作者：Daria Nawrot、Eliška Suchánková、Ondřej Janďourek、Klára Konečná、Pavel Bárta、Martin Doležal、Jan Zitko

  DOI：10.1111/cbdd.13804

  日期：2021.3

  compounds showed broad‐spectrum antimycobacterial activity against M. tuberculosis H37Ra, M. smegmatis and M. aurum. N‐(pyridin‐2‐yl)benzamides were generally more active than N‐(pyridin‐3‐yl)benzamides, indicating that N‐1 in the parental structure of N‐pyrazinylbenzamides might be more important for antimycobacterial activity than N‐4. Marginal antibacterial and antifungal activity was observed for title

  设计并制备了一系列N-吡啶基苯甲酰胺，以研究等排和位置异构对抗分枝杆菌活性的影响。与先前发表的等排N-吡嗪基苯甲酰胺进行比较，试图绘制此类化合物的结构-活性关系。我们总共制备了 44 种不同的化合物，其中 14 种对结核分枝杆菌H37Ra 的最低抑菌浓度 (MIC) 值低于 31.25 µg/ml，最有希望的是N- (5-氯吡啶-2-基)-3-(三氟甲基)苯甲酰胺 ( 23 ) 和N- (6-氯吡啶-2-基)-3-(三氟甲基)苯甲酰胺 ( 24 )，MIC = 7.81 µg/ml (26 µg)米）。五种化合物对结核分枝杆菌H37Ra、耻垢分枝杆菌和金黄色分枝杆菌具有广谱抗分枝杆菌活性。N- (吡啶-2-基)苯甲酰胺通常比N- (吡啶-3-基)苯甲酰胺更具活性，表明N-吡嗪基苯甲酰胺亲本结构中的N -1可能比N-4对抗分枝杆菌活性更重要. 观察到标题化合物的边际抗菌和抗真菌活性。标题化合
• Discovery of VU0431316: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety
  作者：Brittney S. Bates、Alice L. Rodriguez、Andrew S. Felts、Ryan D. Morrison、Daryl F. Venable、Anna L. Blobaum、Frank W. Byers、Kera P. Lawson、J. Scott Daniels、Colleen M. Niswender、Carrie K. Jones、P. Jeffrey Conn、Craig W. Lindsley、Kyle A. Emmitte

  DOI：10.1016/j.bmcl.2014.06.003

  日期：2014.8

  Development of SAR in an aryl ether series of mGlu(5) NAMs leading to the identification of pyrazine analog VU0431316 is described in this Letter. VU0431316 is a potent and selective non-competitive antagonist of mGlu(5) that binds at a known allosteric binding site. VU0431316 demonstrates an attractive DMPK profile, including moderate clearance and good bioavailability in rats. Intraperitoneal (IP) dosing of V1J0431316 in a mouse marble burying model of anxiety, an assay known to be sensitive to mGlu(5) antagonists and other anxiolytics, produced dose proportional effects. (C) 2014 Elsevier Ltd. All rights reserved.